BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steffel J, Ruff CT, Yin O, Braunwald E, Park JG, Murphy SA, Connolly S, Antman EM, Giugliano RP. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. J Am Coll Cardiol 2021;77:1197-207. [PMID: 33663737 DOI: 10.1016/j.jacc.2020.12.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Steffel J, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? J Am Coll Cardiol 2021;77:3232-3. [PMID: 34167651 DOI: 10.1016/j.jacc.2021.04.066] [Reference Citation Analysis]
2 Zhang XL, Zhang XW, Wang TY, Wang HW, Chen Z, Xu B, Xu W. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Circ Cardiovasc Qual Outcomes 2021;14:e007971. [PMID: 34932377 DOI: 10.1161/CIRCOUTCOMES.121.007971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Russo V, Cattaneo D, Giannetti L, Bottino R, Laezza N, Atripaldi U, Clementi E. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. Clin Ther 2021:S0149-2918(21)00247-2. [PMID: 34366151 DOI: 10.1016/j.clinthera.2021.07.003] [Reference Citation Analysis]
4 Gencer B, Eisen A, Berger D, Nordio F, Murphy SA, Grip LT, Chen C, Lanz H, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. Am Heart J 2022;247:24-32. [PMID: 34990581 DOI: 10.1016/j.ahj.2021.12.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gerfer S, Djordjevic I, Eghbalzadeh K, Mader N, Wahlers T, Kuhn E. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review. Ther Adv Cardiovasc Dis 2022;16:17539447221093963. [PMID: 35481366 DOI: 10.1177/17539447221093963] [Reference Citation Analysis]
6 Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M; External reviewers:. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021:euab065. [PMID: 33895845 DOI: 10.1093/europace/euab065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
7 Giugliano RP. Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. European Heart Journal Supplements 2022;24:A1-A10. [DOI: 10.1093/eurheartj/suab150] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Halperin JL, Rashed ER. Low-Dose Anticoagulation for Atrial Fibrillation: When Is a Floor a Trap Door? J Am Coll Cardiol 2021;77:1208-10. [PMID: 33663738 DOI: 10.1016/j.jacc.2021.01.024] [Reference Citation Analysis]
9 Cappannoli L, Galli M, De Cristofaro R, Crea F, D'Amario D. Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? J Am Coll Cardiol 2021;77:3231-2. [PMID: 34167650 DOI: 10.1016/j.jacc.2021.03.340] [Reference Citation Analysis]
10 Kong X, Zhu Y, Pu L, Meng S, Zhao L, Zeng W, Sun W, Wu G, Li H. Efficacy and Safety of Non-recommended Dose of New Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:774109. [PMID: 35004891 DOI: 10.3389/fcvm.2021.774109] [Reference Citation Analysis]